髂股动脉间歇性跛行原发支架置入的成本效果:随机多中心试验两年结果
24个月时分析84例患者数据,支架组平均费用€11 060,对照组€4 787,增量成本效果比为€23 785/QALY,显示支架置入在瑞典指南阈值下具有成本效果。
要点
- 原发支架置入联合BMT与运动建议较单纯BMT与运动建议增加费用€6 273/患者。
- 支架组获得0.26 QALY的增益,ICER为€23 785/QALY。
- 根据瑞典国家指南阈值,原发支架置入具有成本效果。
核心结论
- 股浅动脉原发支架置入治疗间歇性跛行的费用高于单纯运动建议和BMT。
- 伴随健康相关生活质量改善,原发支架置入在瑞典指南阈值下具有成本效果。
- 从成本效果角度看,原发支架置入可作为运动训练建议的辅助治疗。
研究设计与样本
- 患者随机分为原发支架置入联合BMT和运动建议组(支架组)或单纯BMT和运动建议组(对照组)。
- 患者在瑞典七家医院招募,成本效果分析基于24个月时84例有QALY数据的患者。
主要发现
- 支架组平均每患者费用为€11 060,对照组为€4 787,组间差异为€6 273/患者。
- 组间平均QALY差异为0.26,有利于支架组。
- 增量成本效果比(ICER)为€23 785/QALY。
关键数值与推荐
- ICER为€23 785/QALY。
- 瑞典国家指南阈值:ICER < €50 000 - €70 000。
- 英国NICE支付意愿阈值:ICER < £20 000 - £30 000。
临床怎么用
- 在考虑成本效果的医疗体系中,股浅动脉原发支架置入可作为运动训练建议的辅助治疗。
- 需注意结构化运动方案的成功实施和更长随访可能改变这些发现。
局限性
- 成本效果分析仅基于84例有QALY数据的患者。
- 随访时间为24个月,更长随访可能改变结果。
- 结构化运动方案的实施情况可能影响成本效果结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Invasive treatment of intermittent claudication (IC) is commonly performed, despite limited evidence of its cost effectiveness. IC symptoms are mainly caused by atherosclerotic lesions in the superficial femoral artery (SFA), and endovascular treatment is performed frequently. The aim of this study was to investigate its cost effectiveness vs. non-invasive treatment. METHODS: One hundred patients with IC due to lesions in the SFA were randomised to treatment with primary stenting, best medical treatment (BMT) and exercise advice (stent group), or to BMT and exercise advice alone (control group). Patients were recruited at seven hospitals in Sweden. For this analysis of cost effectiveness after 24 months, 84 patients with data on quality adjusted life years (QALY; based on the EuroQol Five Dimensions EQ-5D 3L™ questionnaire) were analysed. Patient registry and imputed cost data were used for accumulated costs regarding hospitalisation and outpatient visits. RESULTS: The mean cost per patient was €11 060 in the stent group and €4 787 in the control group, resulting in a difference of €6 273 per patient between the groups. The difference in mean QALYs between the groups was 0.26, in favour of the stent group, which resulted in an incremental cost effectiveness ratio (ICER) of € 23 785 per QALY. CONCLUSION: The costs associated with primary stenting in the SFA for the treatment of IC were higher than for exercise advice and BMT alone. With concurrent improvement in health related quality of life, primary stenting was a cost effective treatment option according to the Swedish national guidelines (ICER < €50 000 - €70 000) and approaching the UK's National Institute for Health and Care Excellence threshold for willingness to pay (ICER < £20 000 - £30 000). From a cost effectiveness standpoint, primary stenting of the SFA can, in many countries, be used as an adjunct to exercise training advice, but it must be considered that successful implementation of structured exercise programmes and longer follow up may alter these findings.
引用
- Djerf H, Svensson M, Nordanstig J, et al. Editor's Choice - Cost Effectiveness of Primary Stenting in the Superficial Femoral Artery for Intermittent Claudication: Two Year Results of a Randomised Multicentre Trial. Eur J Vasc Endovasc Surg. 2021. PMID: 34454817. doi:10.1016/j.ejvs.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。